Abstract
Vasoreactivity testing, such as intracoronary acetylcholine (ACh) or ergometrine (EM), is defined as Class Ifor the diagnosis of patients with vasospastic angina (VSA) according to recommendations from the Coronary Vasomotion Disorders International Study (COVADIS) group and guidelines from the Japanese Circulation Society (JCS). Although vasoreactivity testing is a clinically useful tool, it carries some risks and limitationsindiagnosing coronary artery spasm. Previous reports on vasoreactivity testing for diagnosing the presence of coronary spasmare summarized from the perspective of Class I. There are several problemssuch as reproducibility, underestimation, overestimation, and inconclusive/nonspecificresults associated with daily spasm. Because provoked spasm caused by intracoronary ACh is not always similar to that caused by intracoronary EM, possibly due to different mediators, supplementary use of these vasoreactivity tests is necessary for cardiologists to diagnose VSAwhen a provoked spasm is not revealed by each vasoactive agent. Cardiologists should understand the imperfection of these vasoreactivity tests when diagnosing patients with VSA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
